Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892043967> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W2892043967 abstract "e18318 Background: Colonoscopy is the “gold standard” for colorectal cancer (CRC) screening. However, adherence rates are low and detection is not optimal. Concomitant aspirin chemoprevention is recommended by US Preventive Task Force, but bleeding complications can be limiting. Variant genotypes in aspirin metabolism can modify CRC and adenoma risk. Genotype guided aspirin (ggASA) use will identify a targeted average-risk population for maximal aspirin benefit while minimizing adverse events rates compared to the general population. We conducted a cost-effectiveness analysis (CEA) of primary chemoprevention in CRC using ggASA compared to no intervention, and colonoscopy ±general aspirin in healthy average-risk individuals. Methods: Our Markov decision analytical model consisted of 5 possible health states: no CRC/polyps, adenoma, pre-clinical CRC, CRC, and death. Model probabilities for CRC and its prevalence were estimated using SEER database and published literature. A microsimulation of 10,000 individuals aged 50-64 years was used to estimate cost-effectiveness from US payer perspective over lifetime. One way and probabilistic sensitivity analyses and model validation results will be reported in the final poster. Results: Our results suggest that compared to colonoscopy and no intervention, ggASA was associated with fewer CRC cases, and CRC-related deaths and MI cases. Compared to colonoscopy + general aspirin, ggASA was associated with fewer bleeding events, similar rates of CRC and CRC-related deaths, and fewer MI cases prevented. From a cost-effectiveness standpoint, ggASA use over a lifetime had the lowest costs and highest quality adjusted life years gained compared to other strategies, if testing costs were ignored. Once genetic testing costs exceeds $63, colonoscopy + general aspirin becomes the most cost effective strategy. Between genetic testing cost of $63-283, the costs of using ggASA per quality adjusted life year gained is below $100,000. Conclusions: Genotype-guided aspirin use precisely identifies an average-risk population, and lowers adverse events rates compared to general aspirin. The economic value of genotype-guided aspirin is dependent on the genetic testing costs." @default.
- W2892043967 created "2018-09-27" @default.
- W2892043967 creator A5008575713 @default.
- W2892043967 creator A5012351723 @default.
- W2892043967 creator A5016535463 @default.
- W2892043967 creator A5024053204 @default.
- W2892043967 creator A5040963321 @default.
- W2892043967 creator A5056739096 @default.
- W2892043967 creator A5083177776 @default.
- W2892043967 date "2017-05-20" @default.
- W2892043967 modified "2023-09-23" @default.
- W2892043967 title "Cost-effectiveness of genotype-guided aspirin use for colorectal cancer prevention." @default.
- W2892043967 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18318" @default.
- W2892043967 hasPublicationYear "2017" @default.
- W2892043967 type Work @default.
- W2892043967 sameAs 2892043967 @default.
- W2892043967 citedByCount "0" @default.
- W2892043967 crossrefType "journal-article" @default.
- W2892043967 hasAuthorship W2892043967A5008575713 @default.
- W2892043967 hasAuthorship W2892043967A5012351723 @default.
- W2892043967 hasAuthorship W2892043967A5016535463 @default.
- W2892043967 hasAuthorship W2892043967A5024053204 @default.
- W2892043967 hasAuthorship W2892043967A5040963321 @default.
- W2892043967 hasAuthorship W2892043967A5056739096 @default.
- W2892043967 hasAuthorship W2892043967A5083177776 @default.
- W2892043967 hasConcept C104317684 @default.
- W2892043967 hasConcept C121608353 @default.
- W2892043967 hasConcept C126322002 @default.
- W2892043967 hasConcept C135763542 @default.
- W2892043967 hasConcept C143998085 @default.
- W2892043967 hasConcept C2777628954 @default.
- W2892043967 hasConcept C526805850 @default.
- W2892043967 hasConcept C54355233 @default.
- W2892043967 hasConcept C71924100 @default.
- W2892043967 hasConcept C86803240 @default.
- W2892043967 hasConceptScore W2892043967C104317684 @default.
- W2892043967 hasConceptScore W2892043967C121608353 @default.
- W2892043967 hasConceptScore W2892043967C126322002 @default.
- W2892043967 hasConceptScore W2892043967C135763542 @default.
- W2892043967 hasConceptScore W2892043967C143998085 @default.
- W2892043967 hasConceptScore W2892043967C2777628954 @default.
- W2892043967 hasConceptScore W2892043967C526805850 @default.
- W2892043967 hasConceptScore W2892043967C54355233 @default.
- W2892043967 hasConceptScore W2892043967C71924100 @default.
- W2892043967 hasConceptScore W2892043967C86803240 @default.
- W2892043967 hasLocation W28920439671 @default.
- W2892043967 hasOpenAccess W2892043967 @default.
- W2892043967 hasPrimaryLocation W28920439671 @default.
- W2892043967 isParatext "false" @default.
- W2892043967 isRetracted "false" @default.
- W2892043967 magId "2892043967" @default.
- W2892043967 workType "article" @default.